Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate that the combination of FOLFIRI plus sunitinib is superior to FOLFIRI plus placebo in prolonging the progression-free survival (PFS) in the first-line treatment of patients with metastatic colorectal cancer.
Critère d'inclusion
- first-line treatment of patients with metastatic colorectal cancer